P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

• Manjunath Krishnappa,
• Divyesh Mandavia,
• Minish Jain,
• Mukesh S,
• Ankit Patel,
• Anshul Agarwal,
• Sanjeev Giri,
• Nirbhay Kumar Tiwari,
• Saravanan Thiyagarajan,
• Mamon Dey,
• Gutta Padmanabha Naidu,
• Murali Ramachandra,
• Akhil Kumar

Affiliations

Manjunath Krishnappa

1 Aurigene Oncology Limited, Bangalore, India

Divyesh Mandavia

1 Aurigene Oncology Limited, Bangalore, India

Minish Jain

2 Ruby Hall Clinic, Pune, India

Mukesh S

3 Mysore Medical College And Research Institute Road, Mysuru, India

Ankit Patel

4 Unique Hospital, Surat, India

Anshul Agarwal

5 Kiran Hospital and Research Center, Surat, India

Sanjeev Giri

1 Aurigene Oncology Limited, Bangalore, India

Nirbhay Kumar Tiwari

1 Aurigene Oncology Limited, Bangalore, India

Saravanan Thiyagarajan

1 Aurigene Oncology Limited, Bangalore, India

Mamon Dey

1 Aurigene Oncology Limited, Bangalore, India

Gutta Padmanabha Naidu

1 Aurigene Oncology Limited, Bangalore, India

Murali Ramachandra

1 Aurigene Oncology Limited, Bangalore, India

Akhil Kumar

1 Aurigene Oncology Limited, Bangalore, India